Hepatitis c virus infection in nephrology patients

Journal of Nephropathology

Volumn 2, Issue 4, 2013, Pages 217-233

  Rostaing, Lionel ^a,b,c   Izopet, Jacques ^b,c   Kamar, Nassim ^a,b,c  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Glomerulonephritis; Hepatitis C; Renal transplantation. Membranoproliferative glomerulonephritis

Indexed keywords

EID: 84894086553     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.12860/JNP.2013.36     Document Type: Review

References (82)

1. Cacoub, P, Costedoat-Chalumeau, N, Lidove, O, Alric, L. Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002; 14:29.
2. Sabry, AA, Sobh, MA, Irving, WL, et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17:239.
3. D’Amico, G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54:650.
4. Morales, J, Morales, E, Andrès, A, Praga, M. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 1999; 8:205.
5. Cosio, FG, Roche, Z, Agarwal, A, et al. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28:752.
6. Altraif, IH, Abdulla, AS, al Sebayel, MI, et al. Hepatitis C associated glomerulonephritis. Am J Nephrol 1995; 15:407.
7. Stehman-Breen, C, Alpers, CE, Fleet, WP, Johnson, RJ. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999; 81:37.
8. Horikoshi, S, Okada, T, Shirato, I, et al. Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic hepatitis C virus hepatitis. Nephron 1993; 64:462.
9. Johnson, RJ, Gretch, DR, Couser, WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46:1700.
10. Coroneos, E, Truong, L, Olivero, J. Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am J Kidney Dis 1997; 29:132.
11. Markowitz, GS, Cheng, JT, Colvin, RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9:2244.
12. Gonzalo, A, Navarro, J, Barcena, R, et al. IgA nephropathy associated with hepatitis C virus infection. Nephron 1995; 69:354.
13. Usalan, C, Erdem, Y, Altun, B, et al. Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. Clin Nephrol 1998; 49:129.
14. Herzenberg, AM, Telford, JJ, De Luca, LG, et al. Thrombotic microangiopathy associated with cryoglobulinemic membranoproliferative glomerulonephritis and hepatitis C. Am J Kidney Dis 1998; 31:521.
15. Arase, Y, Ikeda, K, Murashima, N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 1998; 37:836.
16. McGuire, BM, Julian, BA, Bynon, JSJ, et al. Glomerulonephritis in patients with hepatitis C virus cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.
17. Cruzado, JM, Torras, J, Gil-Vernet, S, Grinyo, JM. Glomerulonephritis associated with hepatitis C virus infection after renal transplantation. Nephrol Dial Transplant 2000; 15:65.
18. Gallay, BJ, Alpers, CE, Davis, CL, et al. Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases. Am J Kidney Dis 1995; 26:662.
19. Baid, S, Pascual, M, Williams, WW, Jr., et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10:146.
20. Tarantino, A, Campise, M, Banfi, G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618.
21. Fabrizi, F, Colucci, P, Ponticelli, C, Locatelli, F. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002; 22:309.
22. Yamabe, H, Inuma, H, Osawa, H, et al. Glomerular deposition of hepatitis C virus in membranoproliferative glomerulonephritis. Nephron 1996; 72:741.
23. Johnson, RJ, Gretch, DR, Yamabe, H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.
24. Johnson, RJ, Willson, R, Yamabe, H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46:1255.
25. Yamabe, H, Johnson, RJ, Gretch, DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220.
26. Agnello, V, Chung, C, Kaplan, LM. A role of hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.
27. Rollino, C, Roccatello, D, Giachino, O, et al. Hepatitis C virus infection and membranous glomerulonephritis. Nephron 1991; 59:319.
28. Davda, R, Peterson, J, Weiner, R, et al. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis 1993; 22:452.
29. Okada, K, Takishita, Y, Shimomura, H, et al. Detectionof hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis. Clin Nephrol 1996; 45:71.
30. Morales, JM, Pascual-Capdevila, J, Campistol, JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63:1634.
31. Morales, E, Alegre, R, Herrero, JC, et al. Hepatitis-C-virus-associated cryoglobulinaemic membranoproliferative glomerulonephritis in patients infected by HIV. Nephrol Dial Transplant 1997; 12:1980.
32. Cheng, JT, Anderson, HLJ, Markowitz, GS, et al. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 1999; 10:1566.
33. Stokes, MB, Chawla, H, Brody, RI, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis 1997; 29:514.
34. Soma, J, Saito, T, Taguma, Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000; 11:690.
35. Crook, ED, Penumalee, S, Gavini, B, Filippova, K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005; 28:2187.
36. Chadban, SJ, Atkins, RC. Glomerulonephritis. Lancet 2005; 365:1797.
37. Misiani, R, Bellavita, P, Fenili, D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751.
38. Sabry, AA, Sobh, MA, Sheaashaa, HA, et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002; 17:1924.
39. Bruchfeld, A, Lindahl, K, Stahle, L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18:1573.
40. Rossi, P, Bertani, T, Baio, P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63:2236.
41. Alric, L, Plaisier, E, Thebault, S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43:617.
42. Gupta, SK, Pittenger, AL, Swan, SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42:1109.
43. Hu, SL, Jaber, BL. Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy. Clin Nephrol 2005; 63:41.
44. Kamar, N, Sandres-Saune, K, Selves, J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42:184.
45. Pham, HP, Feray, C, Samuel, D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54:1311.
46. Kamar, N, Chatelut, E, Manolis, E, et al. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43:140.
47. Bruchfeld, A, Lindahl, K, Schvarcz, R, Stahle, L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24:701.
48. Lin, CC, Philips, L, Xu, C, Yeh, LT. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004; 44:265.
49. Lindahl, K, Schvarcz, R, Bruchfeld, A, Stahle, L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11:84.
50. Kamar, N, Boulestin, A, Selves, J, et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76:61.
51. Zaja, F, De Vita, S, Mazzaro, C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827.
52. Roccatello, D, Baldovino, S, Rossi, D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19:3054.
53. Quartuccio, L, Soardo, G, Romano, G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45:842.
54. Basse, G, Ribes, D, Kamar, N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal-transplant patients. Transplantation 2005; 80:1560.
55. Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virusinfection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2012 Oct 25. doi:pii: S0272-6386(12)01230-9. 10.1053/j.ajkd.2012.08.040.
56. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-34.
57. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 343-53.
58. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835-42. doi: 10.1002/art.34322.
59. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis Arthritis Rheum 2012;64:843-53. doi: 10.1002/art.34331.
60. Ghany MG, Strader DB, Thomas DL, Seef LB. AASLD practice guidelines. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
61. Bocci V, Pacini A, Muscettola M, et al. Renal filtration, absorption, and catabolism of human alpha interferon. J Interferon Res 1981; 1: 347-52.
62. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 Suppl 1: 17-24.
63. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha 2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109-15.
64. Brochot E, Castelain J, Duverlie G, et al. Ribavirin monitoring in chronic hepatitis C therapy: anemia versus efficacy. Antivir Ther 2010; 15: 687-95.
65. Casanovas Taltavull T, Baliellas Comellas C, Cruzado Garrirt JM. Results of hepatitis C virus treatment in patients on hemodialysis: data from published meta-analyses in 2008. Transplant Proc 2009; 41: 2082-4.
66. Fabrizi F, Ganeshan SV, Lunghi G, Messa P, Martin P. Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials. J Viral Hepat. 2008; 15: 600-6.
67. Gordon CE, Uhlig K, Lau J, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008; 51: 263-77.
68. Alavian SM, Tabatabaei SV Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis. 2010; 4:181-94.
69. Rendina M, Schena A, Castellaneta NM, et al. The tretament of chronic hepatitis C with peginterferon alpha-2a (40 kDa) plus ribavirin in hemodialysed patients awaiting renal transplant. J Hepatol 2007, 46: 768-74.
70. Fabrizi F, Messa P, Basile C, Martin P. Hepatic disorders in chronic kidney disease. Nat Rev Nephrol. 2010; 6: 721-6.
71. Liu CH, Liang CC, Liu CJ, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis. 2010;51:541-549.
72. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14:2092-8
73. Nicot F, Kamar N, Mariamé B, et al. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transplant Int 2010; 23: 594-601.
74. Carreno V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol. 2006; 12:6922-5.
75. Pardo M, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Perez-Mota A, Carreno V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther. 2006; 23:1153-9.
76. Carreno V, Bartolome J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol. 2008; 18:139-57.
77. Bartolome J, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Quiroga JA, Palacios R, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol. 2007; 81:7710-5.
78. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol. 2008; 19:2288-92.
79. Kamar N, Nicot F, Izopet J, Rostaing L. Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis. 2009;54:10-2.
80. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51:981-99.
81. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003; 14:2092-8.
82. Nicot F, Kamar N, Mariame B, Rostaing L, Pasquier C, Izopet J. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int. 2010; 23:594-601.